Cognition Therapeutics’ (CGTX) Buy Rating Reaffirmed at Rodman & Renshaw

Cognition Therapeutics (NASDAQ:CGTX)‘s stock had its “buy” rating reissued by stock analysts at Rodman & Renshaw in a research report issued to clients and investors on Tuesday, Benzinga reports. They currently have a $14.00 price objective on the stock.

Several other research analysts also recently weighed in on CGTX. Oppenheimer restated an “outperform” rating and set a $9.00 target price on shares of Cognition Therapeutics in a research note on Wednesday, March 27th. HC Wainwright started coverage on Cognition Therapeutics in a research note on Wednesday, May 29th. They set a “buy” rating and a $10.00 target price on the stock. B. Riley restated a “buy” rating and set a $5.00 target price on shares of Cognition Therapeutics in a research note on Thursday, March 28th. Finally, Chardan Capital began coverage on Cognition Therapeutics in a research note on Thursday, June 6th. They set a “buy” rating and a $11.00 price target on the stock. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $9.17.

Cognition Therapeutics Trading Up 14.7 %

Shares of CGTX traded up $0.25 during trading hours on Tuesday, hitting $1.92. The company had a trading volume of 393,441 shares, compared to its average volume of 179,392. The company has a market capitalization of $76.71 million, a PE ratio of -1.98 and a beta of 1.48. Cognition Therapeutics has a one year low of $0.90 and a one year high of $2.95. The company’s fifty day moving average price is $2.02 and its two-hundred day moving average price is $2.01.

Cognition Therapeutics (NASDAQ:CGTX) last announced its earnings results on Tuesday, May 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Analysts forecast that Cognition Therapeutics will post -0.97 earnings per share for the current year.

Institutional Trading of Cognition Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Tocqueville Asset Management L.P. purchased a new stake in shares of Cognition Therapeutics in the first quarter worth about $47,000. Sigma Planning Corp acquired a new position in Cognition Therapeutics in the 4th quarter worth about $53,000. Levin Capital Strategies L.P. acquired a new position in Cognition Therapeutics in the 1st quarter worth about $55,000. Texas Capital Bank Wealth Management Services Inc acquired a new position in Cognition Therapeutics in the 4th quarter worth about $102,000. Finally, Twin Focus Capital Partners LLC acquired a new position in Cognition Therapeutics in the 4th quarter worth about $173,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.